Skip to main content

View full-text article in PMC

. 2019 Jul 23;110(9):2875–2883. doi: 10.1111/cas.14117

Table 5.

Total dose and relative dose intensity

		SOX		P	CS		P
		Male	Female		Male	Female
		(n = 221)	(n = 73)		(n = 221)	(n = 81)
S‐1
RDI (%)	Median	83.7	75.0	.029^a	83.3	83.3	.411^a
	[Range]	[17.0‐114.5]	[13.0‐100]		[2.4‐112.9]	[11.9‐101.7]
	Mean, SD	81.4, 20.6	75.4, 21.6	.032^b	79.6, 22.7	84.0, 18.0	.081^b
Oxaliplatin/cisplatin
RDI (%)	Median	98.3	75.0	.077^a	87.5	87.5	.958^a
	[Range]	[0‐100]	[28.0‐100]		[0‐134.6]	[0‐102.9]
	Mean, SD	83.5, 20.0	79.1, 20.0	.100^b	80.3, 30.2	82.1, 27.2	.636^b

SOX for 3 cycles, CS for 2 cycles.

Abbreviations: CS; S‐1 plus cisplatin, RDI, relative dose intensity; SD, standard deviation; SOX, S‐1 plus oxaliplatin.

^a

Wilcoxon rank sum test.

^b

t‐test.